About Delcath
Delcath is a company based in New York (United States) founded in 1987. It operates as a HealthTech. The company has 96 employees as of December 31, 2024. Delcath offers products and services including HEPZATO KIT™ and CHEMOSAT®. Delcath operates in a competitive market with competitors including TriSalus Life Sciences, Cooler Heads, Luminate Medical, Embolx and Cognos Therapeutics, among others.
- Headquarter New York, United States
- Employees 96 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Delcath Systems, Inc.
-
Annual Revenue
$37.2 M1701.69as on Dec 31, 2024
-
Net Profit
$-26.39 M44.66as on Dec 31, 2024
-
EBITDA
$-12.18 M67.99as on Dec 31, 2024
-
Latest Funding Round
$16.3 M (USD), Post-IPO
Dec 30, 2024
-
Investors
Canaccord Genuity Group
& 8 more
-
Employee Count
96
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Delcath
Delcath is a publicly listed company on the NASDAQ with ticker symbol DCTH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Delcath
Delcath offers a comprehensive portfolio of products and services, including HEPZATO KIT™ and CHEMOSAT®. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for metastatic Uveal Melanoma in adults provided.
Hepatic delivery system for Melphalan perfusion offered.
Unlock access to complete
Unlock access to complete
Funding Insights of Delcath
- Total Funding Total Funding
- Total Rounds 21
- Last Round Post-IPO — $16.3M
-
First Round
First Round
(01 Apr 2002)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Post-IPO - Delcath | Valuation |
investors |
|
| Mar, 2024 | Amount | Post-IPO - Delcath | Valuation |
investors |
|
| Mar, 2023 | Amount | Post-IPO - Delcath | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Delcath
Delcath has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Canaccord Genuity Group, Jefferies and Vivo Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location | |
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Delcath
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Delcath
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Delcath Comparisons
Competitors of Delcath
Delcath operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TriSalus Life Sciences, Cooler Heads, Luminate Medical, Embolx and Cognos Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drug delivery devices to treat cancers
|
|
| domain | founded_year | HQ Location |
Developer of cold cap system to prevent chemotherapy side effects
|
|
| domain | founded_year | HQ Location |
Developer of a medical device to prevent hair loss during chemotherapy
|
|
| domain | founded_year | HQ Location |
Catheter-based system for localized cancer therapy is being developed.
|
|
| domain | founded_year | HQ Location |
Cognos Therapeutics is focused on innovative neurological and oncological treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Delcath
Frequently Asked Questions about Delcath
When was Delcath founded?
Delcath was founded in 1987 and raised its 1st funding round 15 years after it was founded.
Where is Delcath located?
Delcath is headquartered in New York, United States. It is registered at New York, New York, United States.
How many employees does Delcath have?
As of Dec 31, 2024, the latest employee count at Delcath is 96.
What is the annual revenue of Delcath?
Annual revenue of Delcath is $37.2M as on Dec 31, 2024.
What does Delcath do?
Delcath Systems, Inc. is recognized as an interventional oncology company dedicated to the treatment of primary and metastatic liver cancers. Solutions are developed to provide targeted, safe, and effective minimally-invasive treatments for patients. The impact of liver cancer, affecting 1.2 million people globally each year, is addressed through innovative products like HEPZATO KIT for metastatic Uveal Melanoma in the United States and CHEMOSAT Hepatic Delivery System in Europe. Commitment is shown in revolutionizing care for liver cancer patients by exploring beyond conventional treatment options.
Who are the top competitors of Delcath?
Delcath's top competitors include TriSalus Life Sciences, Cooler Heads and Cognos Therapeutics.
What products or services does Delcath offer?
Delcath offers HEPZATO KIT™ and CHEMOSAT®.
Is Delcath publicly traded?
Yes, Delcath is publicly traded on NASDAQ under the ticker symbol DCTH.
Who are Delcath's investors?
Delcath has 9 investors. Key investors include Canaccord Genuity Group, Jefferies, Vivo Capital, Logos Capital, and BVF Partners.
What is Delcath's ticker symbol?
The ticker symbol of Delcath is DCTH on NASDAQ.